ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2025
Cost-effectiveness of a ketoanalogue-supplemented very low-protein diet in CKD.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is a global health concern with significant economic implications, particularly in the management of end-stage renal disease (ESRD), which often requires kidney replacement therapy such as dialysis or transplantation. The rising incidence of ESRD is expected to increase healthcare costs substantially by 2030. Dietary protein restriction is a cornerstone of managing CKD progression, and the use of ketoanalogues in very low-protein diets (VLPD) has shown promise in delaying dialysis initiation. This study evaluates the cost-effectiveness of a vegetarian ketoanalogue-supplemented VLPD (s-VLPD) compared with a low-protein diet (LPD) in patients with CKD stages 4 and 5 in Italy.
methodsA Markov model was developed to simulate the health outcomes and costs for patients with CKD stages 4 or 5, treated with either s-VLPD or LPD. The analysis was conducted from both the Italian National Healthcare Service (NHS) and societal perspectives. Healthcare costs considered were: ketoanalogue supplementation, dialysis and diet monitoring. Overall survival and quality-adjusted life years (QALYs) were used as effectiveness outcomes. Sensitivity analyses, including deterministic and probabilistic approaches, assessed the robustness of the results.
resultsThe s-VLPD strategy led to improved survival (+0.60 years) and increased QALYs (+0.49) compared with LPD, along with cost savings of approximately €34 000 per patient from the NHS perspective. From the societal perspective, s-VLPD resulted in a cost saving of €59 147 per patient. Sensitivity analyses confirmed that s-VLPD remains a dominant strategy, demonstrating both clinical and economic advantages.
conclusions-VLPD is a cost-effective strategy for managing CKD stages 4 and 5, offering improved patient outcomes and significant cost savings. The findings support the integration of s-VLPD in routine clinical practice, helping delay dialysis initiation, reduce the financial burden on healthcare systems and improve patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.